Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Descovy noninferior to Truvada for PrEP

Publish date:: March 13, 2019

Key clinical point: Descovy for PrEP is going to be a tough sell when generic Truvada hits the market.

Major finding: PrEP failed in just two men at high risk for HIV, one in the Descovy arm and one in the Truvada arm. The drugs were equally safe.

Study details: Randomized trial involving more than 5,000 men.

Disclosures: The work was funded by Gilead; four investigators, including the senior investigator, were employees. The presenter was an investigator for the company.

Citation:

Hare CB et al. CROI 2019, Abstract 104 LB.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Infectious Diseases

Obesity, hypoxia predict severity in children with COVID-19,

Prophylactic HIV treatment in female STI patients is rare,

Combo DAA treatments may benefit patients with resistant HCV genotype 3,

Pronounced racial differences in HBsAg loss after stopping nucleos(t)ide,

Opt-out policy at a syringe service program increased HIV/HCV testing,